Denali Therapeutics Stock Performance
| DNLI Stock | USD 22.53 1.06 4.49% |
The firm shows a Beta (market volatility) of 1.58, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Denali Therapeutics will likely underperform. At this point, Denali Therapeutics has a negative expected return of -0.48%. Please make sure to confirm Denali Therapeutics' maximum drawdown, as well as the relationship between the accumulation distribution and day typical price , to decide if Denali Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Denali Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in March 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Actual Historical Performance (%)
One Day Return (4.49) | Five Day Return (3.59) | Year To Date Return 8.11 | Ten Year Return 5.03 | All Time Return 5.03 |
1 | Disposition of 1020 shares by Sato Vicki L of Denali Therapeutics at 30.0 subject to Rule 16b-3 | 11/07/2024 |
2 | Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging | 11/08/2024 |
3 | Acquisition by Sato Vicki L of 17901 shares of Denali Therapeutics at 18.56 subject to Rule 16b-3 | 11/19/2024 |
4 | Disposition of 20516 shares by Schuth Alexander O. of Denali Therapeutics at 0.68 subject to Rule 16b-3 | 11/22/2024 |
5 | Disposition of 17845 shares by Ho Carole of Denali Therapeutics at 0.68 subject to Rule 16b-3 | 11/25/2024 |
6 | Denali Starts Dosing in Phase II Parkinsons Disease Study | 12/06/2024 |
7 | Disposition of 6708 shares by Schuth Alexander O. of Denali Therapeutics at 5.28 subject to Rule 16b-3 | 12/27/2024 |
8 | Disposition of 30000 shares by Steve Krognes of Denali Therapeutics at 20.25 subject to Rule 16b-3 | 12/31/2024 |
9 | Disposition of 3080 shares by Sato Vicki L of Denali Therapeutics at 20.91 subject to Rule 16b-3 | 01/02/2025 |
10 | Acquisition by Ho Carole of 162540 shares of Denali Therapeutics at 21.26 subject to Rule 16b-3 | 01/03/2025 |
11 | Denali Therapeutics Inc Announces Topline Results from HEALEY ALS Platform Trial | 01/06/2025 |
12 | Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp ... | 01/08/2025 |
13 | Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance ... | 01/13/2025 |
14 | Why Is Denali Therapeutics Stock Trading Higher On Wednesday | 01/15/2025 |
15 | Acquisition by Klein Peter S of 17901 shares of Denali Therapeutics at 18.56 subject to Rule 16b-3 | 01/22/2025 |
16 | Acquisition by Ryan Watts of 162540 shares of Denali Therapeutics at 21.26 subject to Rule 16b-3 | 01/24/2025 |
17 | Amgen Set to Report Q4 Earnings Is a Beat in the Cards | 01/29/2025 |
18 | What is Zacks Researchs Estimate for DNLI FY2024 Earnings | 01/31/2025 |
19 | Denali Therapeutics Inc Announces Promising Long-Term Data for Hunter Syndrome Treatment | 02/06/2025 |
| Begin Period Cash Flow | 219.5 M |
Denali |
Denali Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,158 in Denali Therapeutics on November 9, 2024 and sell it today you would lose (905.00) from holding Denali Therapeutics or give up 28.66% of portfolio value over 90 days. Denali Therapeutics is currently does not generate positive expected returns and assumes 4.1912% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Denali, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Denali Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Denali Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Denali Therapeutics, and traders can use it to determine the average amount a Denali Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1155
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DNLI |
Estimated Market Risk
| 4.19 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Denali Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Denali Therapeutics by adding Denali Therapeutics to a well-diversified portfolio.
Denali Therapeutics Fundamentals Growth
Denali Stock prices reflect investors' perceptions of the future prospects and financial health of Denali Therapeutics, and Denali Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Denali Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 2.61 B | ||||
| Shares Outstanding | 143.92 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 3,339 X | ||||
| Revenue | 330.53 M | ||||
| Gross Profit | (412.36 M) | ||||
| EBITDA | (179.97 M) | ||||
| Net Income | (145.22 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 52.24 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 9.17 X | ||||
| Cash Flow From Operations | (357.99 M) | ||||
| Earnings Per Share | (2.76) X | ||||
| Market Capitalization | 3.24 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 986.15 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
About Denali Therapeutics Performance
By evaluating Denali Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Denali Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Denali Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Denali Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (298.46) | (313.38) | |
| Return On Tangible Assets | (0.11) | (0.12) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.11) | (0.12) | |
| Return On Equity | (0.16) | (0.17) |
Things to note about Denali Therapeutics performance evaluation
Checking the ongoing alerts about Denali Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Denali Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Denali Therapeutics generated a negative expected return over the last 90 days | |
| Denali Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (412.36 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Denali Therapeutics Inc Announces Promising Long-Term Data for Hunter Syndrome Treatment |
- Analyzing Denali Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Denali Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Denali Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Denali Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Denali Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Denali Therapeutics' stock. These opinions can provide insight into Denali Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stocks Directory Find actively traded stocks across global markets |